Chiamaka Esther Amaefule

Chiamaka Esther Amaefule

Auto-generated profile, based on publicly available information

Chiamaka Esther Amaefule

BARC (Barts Research Centre for Women’s Health), Institute of Population Health Sciences, Queen Mary University of London Barts and The London School of Medicine and Dentistry, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
CAChiamaka Esther Amaefule
Chiamaka Esther Amaefule
ZDZoe Drymoussi
Zoe Drymoussi
FCFrancisco Jose Gonzalez Carreras
Francisco Jose Gonzalez Carreras
MLMaria del Carmen Pardo Llorente
Maria del Carmen Pardo Llorente
DLDoris Lanz
Doris Lanz
STShakila Thangaratinam
Shakila Thangaratinam
Objectives: To determine the feasibility and acceptability of conducting a randomised trial on the effects of myo-inositol in preventing gestational diabetes in high-risk pregnant women. Design: A multicentre, double-blind, placebo-controlled, pilot randomised trial with nested qualitative evaluation. Setting: Five inner city UK National Health Service hospitals Participants: Multiethnic pregnant women at 12 +0 and 15 +6 weeks’ gestation with risk factors for gestational diabetes. Interventions: 2 g of myo-inositol or placebo, both included 200 µg folic acid, twice daily until delivery. Primary outcome measures: Rates of recruitment, randomisation, adherence and follow-up. Secondary outcome measures: Glycaemic indices (including homoeostatic model assessment-insulin resistance HOMA-IR), gestational diabetes (diagnosed using oral glucose tolerance test at 28 weeks and by delivery), maternal, perinatal outcomes, acceptability of intervention and costs. Results: Of the 1326 women screened, 58% (773/1326) were potentially eligible, and 27% (205/773) were recruited. We randomised 97% (198/205) of all recruited women (99 each in intervention and placebo arms) and ascertained outcomes in 90% of women (178/198) by delivery. The mean adherence was 52% (SD 44) at 28 weeks’ and 34% (SD 41) at 36 weeks’ gestation. HOMA-IR and serum insulin levels were lower in the myo-inositol vs placebo arm (mean difference −0.6, 95% CI −1.2 to 0.0 and −2.69, 95% CI −5.26 to −0.18, respectively). The study procedures were acceptable to women and healthcare professionals. Women who perceived themselves at high risk of gestational diabetes were more likely to participate and adhere to the intervention. The powder form of myo-inositol and placebo, along with nausea in pregnancy were key barriers to adherence. Conclusions: A future trial on myo-inositol versus placebo to prevent gestational diabetes is feasible. The intervention will need to be delivered in a non-powder form to improve adherence. There is a signal for efficacy in reducing insulin resistance in pregnancy with myo-inositol. Trial registration number: ISRCTN48872100 .

24 September 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
CAChiamaka Esther Amaefule
Chiamaka Esther Amaefule
ZDZoe Drymoussi
Zoe Drymoussi
JDJulie Dodds
Julie Dodds
LSLorna Sweeney
Lorna Sweeney
EPElena Pizzo
Elena Pizzo
STShakila Thangaratinam
Shakila Thangaratinam
Introduction: Gestational diabetes increases maternal and offspring complications in pregnancy and cardiovascular complications in the long term. The nutritional supplement myo -inositol may prevent gestational diabetes; however, further evaluation is required, especially in multiethnic high-risk mothers. Our pilot trial on myo -inositol to prevent gestational diabetes will evaluate trial processes, assess acceptability to mothers and obtain preliminary estimates of effect and cost data prior to a large full-scale trial. Methods and analysis: EMmY is a multicentre, placebo-controlled, double-blind, pilot, randomised trial, with qualitative evaluation. We will recruit pregnant women at 12–15 +6 weeks’ gestation, with gestational diabetes risk factors, from five maternity units in England between 2018 and 2019. We will randomise 200 women to take either 2 g of myo -inositol powder (intervention) or placebo, twice daily until delivery. We will assess rates of recruitment, randomisation, adherence to intervention and follow-up. Gestational diabetes will be diagnosed at 24–28 weeks as per the National Institute for Health and Care Excellence (NICE) criteria (fasting plasma glucose: ≥5.6 mmol/L and 2-hour plasma glucose: ≥7.8 mmol/L). We will assess the effects of myo -inositol on glycaemic indices at 28 weeks and on other maternal, fetal and neonatal outcomes at postnatal discharge. Qualitative evaluation will explore the acceptability of the trial and the intervention among women and healthcare professionals. Cost data and health-related quality of life measures will be captured. We will summarise feasibility outcomes using standard methods for proportions and other descriptive statistics, and where appropriate, report point estimates of effect sizes (eg, mean differences and relative risks) and associated 95% CIs. Ethics and dissemination: Ethical approval was obtained through the London Queen Square Research Ethics Committee (17/LO/1741). Study findings will be submitted for publication in peer-reviewed journals. Newsletters will be made available to participants, healthcare professionals and members of Katie’s Team (a patient and public advisory group) to disseminate. Trial registration number: ISRCTN48872100. Protocol version and date: Version 4.0, 15 January 2018.

17 May 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
CAChiamaka Esther Amaefule
Chiamaka Esther Amaefule
ABAngeliki Bolou
Angeliki Bolou
ZDZoe Drymoussi
Zoe Drymoussi
FCFrancisco Jose Gonzalez Carreras
Francisco Jose Gonzalez Carreras
MLMaria del Carmen Pardo Llorente
Maria del Carmen Pardo Llorente
STShakila Thangaratinam
Shakila Thangaratinam
Introduction Up to half of all women diagnosed with gestational diabetes mellitus develop type 2 diabetes within 5 years after delivery. Metformin is effective in preventing type 2 diabetes in high-risk non-pregnant individuals, but its effect when commenced in the postnatal period is not known. We plan to assess the feasibility of evaluating metformin versus placebo in minimising the risk of dysglycaemia including type 2 diabetes after delivery in postnatal women with a history of gestational diabetes through a randomised trial. Methods and analysis Optimising health outcomes with Metformin to prevent diAbetes After pregnancy (OMAhA) is a multicentre placebo-controlled double-blind randomised feasibility trial, where we will randomly allocate 160 postnatal women with gestational diabetes treated with medication to either metformin (intervention) or placebo (control) tablets to be taken until 1 year after delivery. The primary outcomes are rates of recruitment, randomisation, adherence and attrition. The secondary outcomes are maternal dysglycaemia, cost and quality of life outcomes in both arms, and acceptability of the study and intervention, which will be evaluated through a nested qualitative study. Feasibility outcomes will be summarised using descriptive statistics, point estimates and 95% CIs. Ethics and dissemination The OMAhA study received ethics approval from the London-Brent Research Ethics Committee (18/LO/0505). Trial findings will be published in a peer-reviewed journal, disseminated at conferences, through our Patient and Public Involvement advisory group (Katie’s Team) and through social media platforms. Trial registration number ISRCTN20930880